Petrelintide^↗

"petrelintide"[Title/Abstract] OR "ZP8396"[Title/Abstract]

• Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
• Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

1. PubMed 42017294 — include: Two original randomized phase 1 human studies reported in one paper; full-text reading and study-family comparison are separate review steps. Study families: EudraCT-2021-001712-28; EudraCT-2022-001744-26.
   Structured full-text reading · PMC13243934

   This is an editorial structured reading, not a validated risk-of-bias score.

   Read the source full text (Europe PMC XML) ↗

   Randomization and masking

   Methods describe an independent unblinded randomization programmer, masked identical vials, and blinded participants and trial staff. Two trials and their cohorts are reported in one paper.

   Missing data

   Results report 133 randomized and 132 treated. All participants completed the single-exposure trial and the first multiple-exposure part; three active-group participants discontinued in the later part. Weight estimates include a post hoc repeated-measures model.

   Outcome selection

   Safety and tolerability were primary; body-weight changes were secondary. No formal sample-size calculation was performed. Registry protocols and supplementary tables have not yet been independently reconciled, so selective-reporting risk remains unresolved.

   Applicability

   One German research center enrolled otherwise healthy adults with normal weight, overweight or obesity. The later part included 48 people, all White and mostly men; observation lasted 16 weeks. No active comparator supports claims of superior tolerability.

   Funding and conflicts

   Zealand Pharma sponsored the trials and manuscript and participated in design, collection and publication. Several authors were employees or shareholders. This is a potential influence to consider, not evidence that results are false.

   Registry comparison

   The paper identifies EudraCT 2021-001712-28 and 2022-001744-26. Independent comparison of registered outcomes, amendments and supplements is still pending.

   Reviewed 2026-09-15; source SHA-256 82103b805848b3cff44466a271f84aecc0cd468cad189c04690c0593e575a7d5.

2. PubMed 42586227 — exclude: Review of the amylin evidence base, not a new administered human study.
3. PubMed 42452898 — exclude: Review of the amylin evidence base, not a new administered human study.
4. PubMed 41747885 — exclude: Review of the amylin evidence base, not a new administered human study.
5. PubMed 41344603 — exclude: Review of the amylin evidence base, not a new administered human study.
6. PubMed 41217931 — exclude: Compound-development and preclinical potency report; the abstract describes clinical development rather than reporting a human administration trial.
7. PubMed 40608546 — exclude: Preclinical development of a different analogue, BGM1812, not a human petrelintide administration report.

petrelintide OR ZP8396

• Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
• Other registries and unregistered studies are outside this search.
• Petrelintide has one ambiguous registry identity; the second trial publication linkage remains incompletely reconciled.

Showing 9 of 9 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

1. ClinicalTrials.gov NCT07338214 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07338214.
2. ClinicalTrials.gov NCT05096598 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05096598.
3. ClinicalTrials.gov NCT06926842 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06926842.
4. ClinicalTrials.gov NCT06662539 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06662539.
5. ClinicalTrials.gov NCT07076030 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07076030.
6. ClinicalTrials.gov NCT05613387 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05613387.
7. ClinicalTrials.gov NCT07589686 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07589686.
8. ClinicalTrials.gov NCT07682818 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07682818.
9. ClinicalTrials.gov NCT06951854 — unresolved: Autism NV01-A02 record contains a conflicting placebo name mentioning ZP8396; identity is unresolved.

products.active_ingredients.name:"PETRELINTIDE" OR products.active_ingredients.name:"ZP8396"

• This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

• Complete source-document appraisal and national European sources remain open.
• Zero identity matches apply only to these feed fields and terms.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

• Complete source-document appraisal and national European sources remain open.
• Zero identity matches apply only to these feed fields and terms.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

• Complete source-document appraisal and national European sources remain open.
• Zero identity matches apply only to these feed fields and terms.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.